- Continuing on its mission of mastering biology to advance human health, 10x Genomics (NASDAQ:TXG) to acquire ReadCoor for cash and stock consideration of $350M.
- The announcement follows acquisition of Stockholm-based CartaNA AB, developers of In Situ RNA analysis technology, in late August.
- As a result of these transactions, 10x Genomics will acquire over 110 patents and applications that cover multiple foundational In Situ analysis approaches.
- These add to its already comprehensive patent portfolio of over 825 issued patents and applications.
- Source: Press Release
- https://seekingalpha.com/news/3619942-10x-genomics-advances-emerging-field-of-in-situ-analysis-two-acquisitions
Monday, October 5, 2020
10x Genomics advances in emerging in situ analysis with 2 acquisitions
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.